company background image
4530

Hisamitsu Pharmaceutical TSE:4530 Stock Report

Last Price

JPÂ¥3.65k

Market Cap

JPÂ¥282.2b

7D

0.1%

1Y

8.9%

Updated

06 Jun, 2023

Data

Company Financials +

Hisamitsu Pharmaceutical Co., Inc.

TSE:4530 Stock Report

Mkt Cap: JPÂ¥282.2b

4530 Stock Overview

Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals, quasi-drugs, and medical devices in Japan.

4530 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth3/6
Past Performance4/6
Financial Health6/6
Dividends4/6

My Notes

Capture your thoughts, links and company narrative

Hisamitsu Pharmaceutical Co., Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Hisamitsu Pharmaceutical
Historical stock prices
Current Share PriceJPÂ¥3,649.00
52 Week HighJPÂ¥4,065.00
52 Week LowJPÂ¥3,230.00
Beta0.56
1 Month Change-3.08%
3 Month Change-3.34%
1 Year Change8.93%
3 Year Change-33.78%
5 Year Change-60.47%
Change since IPO727.44%

Recent News & Updates

Recent updates

Shareholder Returns

4530JP PharmaceuticalsJP Market
7D0.1%2.7%2.6%
1Y8.9%18.8%13.6%

Return vs Industry: 4530 underperformed the JP Pharmaceuticals industry which returned 18.8% over the past year.

Return vs Market: 4530 underperformed the JP Market which returned 13.6% over the past year.

Price Volatility

Is 4530's price volatile compared to industry and market?
4530 volatility
4530 Average Weekly Movement2.7%
Pharmaceuticals Industry Average Movement3.4%
Market Average Movement3.7%
10% most volatile stocks in JP Market7.8%
10% least volatile stocks in JP Market2.1%

Stable Share Price: 4530 is less volatile than 75% of JP stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: 4530's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
18472,769Kazuhide Nakatomihttps://www.hisamitsu.co.jp

Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals, quasi-drugs, and medical devices in Japan. The company provides external pain relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; and BUTENALOCK, a remedy for athlete's foot, as well as ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, transdermal analgesic anti-inflammatory drug; patches for female hormone, asthma treatment, and treatment for overactive bladders.

Hisamitsu Pharmaceutical Co., Inc. Fundamentals Summary

How do Hisamitsu Pharmaceutical's earnings and revenue compare to its market cap?
4530 fundamental statistics
Market CapJPÂ¥282.21b
Earnings (TTM)JPÂ¥11.74b
Revenue (TTM)JPÂ¥128.33b

24.2x

P/E Ratio

2.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
4530 income statement (TTM)
RevenueJPÂ¥128.33b
Cost of RevenueJPÂ¥55.63b
Gross ProfitJPÂ¥72.70b
Other ExpensesJPÂ¥60.96b
EarningsJPÂ¥11.74b

Last Reported Earnings

Feb 28, 2023

Next Earnings Date

Jul 13, 2023

Earnings per share (EPS)151.03
Gross Margin56.65%
Net Profit Margin9.15%
Debt/Equity Ratio0.5%

How did 4530 perform over the long term?

See historical performance and comparison

Dividends

2.3%

Current Dividend Yield

52%

Payout Ratio